Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2025.Jan.22

Announcement on behalf of OBIGEN that TFDA clears OBI-858’s IND application for repeat-dose Phase II safety study

2025.Jan.03

OBI completed the capital reduction registration for the Restricted Stock Awards cancelled

2024.Dec.23

OBI Pharma and GlyTech have entered into a GlycOBI marketing agreement in Japan and a material transfer agreement

2024.Dec.10

Announcement on behalf of OBIGEN to acquire the worldwide intellectual property rights of OBI-858 and sign the technology transfer agreement

2024.Dec.10

OBI’s BOD resolved to transfer the worldwide intellectual property rights of OBI-858 and sign the technology transfer agreement

2024.Dec.10

The Company’s BOD resolved the redemption and cancellation of the Restricted Stock Awards and the record date of capital reduction

2024.Dec.06

Announcement of the expiration of the Company's 2024 cash capital increase call period and the issuance of stocks

2024.Nov.26

Announcement on behalf of OBIGEN that it has filed the application of repeat-dose Phase II safety study for OBI-858 to TFDA

2024.Nov.15

OBI is invited to present the current development status of its products and technology platforms at the investor conference hosted by MasterLink

2024.Nov.12

Announcement of the Company's full receipt of cash capital increase in 2024 and the reference date of capital increase

News

Latest News

Events

Latest events